NU7441 (KU-57788)

Name: NU7441 (KU-57788)
Brand: Selleck Chemicals
SKU: S2638
Rating: 5 (152 reviews)

For research use only.

Catalog No.S2638

152 publications

CAS No. 503468-95-9

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Selleck's NU7441 (KU-57788) has been cited by 152 publications

Immunity, 2021, S1074-7613(21)00069-8

PubMed: 33667382 ( click the link to review the publication )

Nature, 2020, 10.1038/s41586-020-2960-y

PubMed: 33239783 ( click the link to review the publication )

Nature, 2019, 74(7779):571-574

PubMed: 31645724 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):396-410

PubMed: 30205044 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Int J Biol Sci, 2021, 17(4): 1026-1040

PubMed: N/A ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-020-00577-1

PubMed: 33414509 ( click the link to review the publication )

Mol Biol Rep, 2021, 10.1007/s11033-020-06124-9

PubMed: 33389482 ( click the link to review the publication )

Sci Transl Med, 2021, 13(580)eabc4465

PubMed: 33568520 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab051

PubMed: 33591315 ( click the link to review the publication )

Blood, 2020, 5 pii: blood

PubMed: 32369572 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30723-1

PubMed: 33152268 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6182

PubMed: 33273464 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa782

PubMed: 33010172 ( click the link to review the publication )

Sci Immunol, 2020, 5(43)

PubMed: 31980485 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-2269

PubMed: 32967938 ( click the link to review the publication )

J Cell Biol, 2020, 219(11)e202001063

PubMed: 33007086 ( click the link to review the publication )

Cell Rep, 2020, 32(8):108068

PubMed: 32846126 ( click the link to review the publication )

Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )
Cell Rep, 2020, 33(2):108240

PubMed: 33053351 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 4;5(1):20

PubMed: 32296021 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

Front Oncol, 2020, 10:575711

PubMed: 33178606 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6383

PubMed: 32887472 ( click the link to review the publication )

Int J Oncol, 2020, 57(4):939-955

PubMed: 32945394 ( click the link to review the publication )

Int J Radiat Biol, 2020, 1-7

PubMed: 33074046 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29927

PubMed: 32686190 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(2):736-747

PubMed: 31740976 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2356

PubMed: 32825402 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )

Oncotarget, 2020, 11(7):699-726

PubMed: 32133046 ( click the link to review the publication )

NAR Cancer, 2020, 2(2):zcaa006

PubMed: 32743550 ( click the link to review the publication )

Elife, 2020, 9:e57894

PubMed: 32628111 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1673-1684

PubMed: 32186748 ( click the link to review the publication )

Cell Rep, 2020, 32(6):108018

PubMed: 32783940 ( click the link to review the publication )

Toxicol Lett, 2020, 318:104-113

PubMed: 31672611 ( click the link to review the publication )

Biomed Pharmacother, 2020, 129:110427

PubMed: 32574974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5304

PubMed: 31757956 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2866

PubMed: 31253785 ( click the link to review the publication )
Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Genes Dev, 2019, 33(17-18):1175-1190

PubMed: 31395742 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

J Cell Biol, 2019, 218(7):2113-2123

PubMed: 31123184 ( click the link to review the publication )

Cell Rep, 2019, 29(11):3708-3725.e5

PubMed: 31825846 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31480356 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(1):1138-1150

PubMed: 30106602 ( click the link to review the publication )

FASEB J, 2019, 33(11):11668-11681

PubMed: 31348687 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007925

PubMed: 30716077 ( click the link to review the publication )

J Environ Manage, 2019, 244:77-82

PubMed: 31108313 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)E6316

PubMed: 31847370 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Mol Cell Biol, 2019, 39(24)e00181-19

PubMed: 31591143 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 371(2):320-326

PubMed: 31455631 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Front Physiol, 2019, 10:616

PubMed: 31178753 ( click the link to review the publication )

BMC Pulm Med, 2019, 19(1-:165

PubMed: 31464599 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04605-0

PubMed: 31020489 ( click the link to review the publication )
Mol Biol Rep, 2019, 10.1007/s11033-019-05105-x

PubMed: 31583565 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(7):1315-1326

PubMed: 31141305 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(18):9467-9479

PubMed: 31396623 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(16):8838-8859

PubMed: 31329944 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Cell Rep, 2018, 24(4):987-1000

PubMed: 30044993 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:68-74

PubMed: 30017059 ( click the link to review the publication )

Mol Biol Cell, 2018, 29(15):1786-1797

PubMed: 29897835 ( click the link to review the publication )

Int J Mol Sci, 2018,

PubMed: 30115874 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9685

PubMed: 29946146 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(17):8926-8939

PubMed: 30113698 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )
JCI Insight, 2018, 3(3)98096

PubMed: 29415883 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(1):244-254

PubMed: 28069995 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(9):790-803

PubMed: 28775208 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(18):4745-4754

PubMed: 28754673 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

EMBO Rep, 2017, 18(8):1412-1428

PubMed: 28615293 ( click the link to review the publication )

Cell Death Discov, 2017, 3:17072

PubMed: 29090098 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 92:164-172

PubMed: 28827033 ( click the link to review the publication )

Radiat Res, 2017, 188(6):597-604

PubMed: 28952912 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181608

PubMed: 28750002 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(2):2916-2935

PubMed: 27935866 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(11):1196-1207

PubMed: 27723717 ( click the link to review the publication )

blood, 2016, 10.1182/blood-2016-02-700328

PubMed: ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 35(5):577-586

PubMed: 25893305 ( click the link to review the publication )

Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

Cell Death Dis, 2016, 7(7):e2316

PubMed: 27468692 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )
PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163049

PubMed: 27643854 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(11):5204-17

PubMed: 27001513 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(8):3695-712

PubMed: 26843428 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65504-65513

PubMed: 27602767 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(9):1158-68

PubMed: 26237645 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genome Med, 2015, 10.1186/s13073-015-0215-6

PubMed: 26307031 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(8):1896-906

PubMed: 26026052 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Cell Cycle, 2015, 14(23):3713-24

PubMed: 26505547 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26065416 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14005-25

PubMed: 26087309 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253 ( click the link to review the publication )

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4282-94

PubMed: 24894717 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )
Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed: ( click the link to review the publication )

Uppsala University, 2014, Department of Radiology

PubMed: ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description

Targets

DNA-PK ^[1] (Cell-free assay)	mTOR ^[1] (cell-free assay)	PI3K ^[1] (cell-free assay)
14 nM	1.7 μM	5 μM

In vitro

NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[7].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
NCI-H1770	M2fMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUDJR\|UxRTBwMEKxOFMh\|ryP	NWftWGFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
A172	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2HKe2lEPTB;MD6xOVMyPiEQvF2=	NXv3fIdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H526	NUDQRXViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEjwVYVKSzVyPUCuNlg1ODdizszN	NFrYXG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HDLM-2	M2[5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MU\JR\|UxRTBwM{KzOFUh\|ryP	NY\lb2hFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HuO-3N1	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3;McmlEPTB;MD60OlY{PiEQvF2=	MnvoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlqxTWM2OD1yLk[wPVk1KM7:TR?=	NULmXWs3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SK-N-AS	M2XL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWXJR\|UxRTBwNkKyNVYh\|ryP	M1PzO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LoVo	M4foZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXfhd2U2UUN3ME2wMlg3PzR7IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LAMA-84	NFm0epRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYPJR\|UxRTBwOUi4N\|Mh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CTB-1	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1LzbmlEPTB;MT6xNVU1PiEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KP-N-YS	NUizXplLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWDJR\|UxRTFwMUSyN\|Eh\|ryP	M{G0dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HH	NXzpeWlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlnsTWM2OD1zLkG4NFk{KM7:TR?=	NYDrSI91RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CHL-1	M13HO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3fKZWlEPTB;MT6yNVM3QCEQvF2=	NHnHV5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NB7	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYPJR\|UxRTFwMkS3OFUh\|ryP	MorHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HL-60	NH34fIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH\TflhKSzVyPUGuN\|gyQSEQvF2=	M2HhOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
639-V	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mk[xTWM2OD1zLkS0NVI5KM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H1793	NW\VWYJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHfVVpRKSzVyPUGuOFU5PCEQvF2=	NUXVc4ZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NEC8	M2qyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1PvRWlEPTB;MT61OVM2KM7:TR?=	Mn7PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
PA-1	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NETKNnNKSzVyPUGuOVgzQTRizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-423MG	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIW0TYFKSzVyPUGuOlk{PjFizszN	NInLTVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H292	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGHoNodKSzVyPUGuO\|QxOTNizszN	NH;LTIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-MEL-1	NWjnfnZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3u1cmlEPTB;MT63PVQ4QSEQvF2=	M2nlclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LB2241-RCC	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlnjTWM2OD1{LkG0NVQ3KM7:TR?=	NI\GdHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-MEL-3	NXTxOZNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{\MU2lEPTB;Mj6xOlQ6KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MHH-PREB-1	MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXHjSnd[UUN3ME2yMlE3PjB7IN88US=>	NWL5NXplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BFTC-905	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGfTbGtKSzVyPUKuNVY3QDdizszN	NWDVXVlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	M3vJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1qwWWlEPTB;Mj6xPVkxQSEQvF2=	NYrxU3lPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
G-361	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXvONWNZUUN3ME2yMlIyPjhizszN	M4LPRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MOLT-4	NHnuN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M17IUGlEPTB;Mj6yNVg5QCEQvF2=	MoLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
DEL	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3nKfmlEPTB;Mj6zOVU3PCEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MV-4-11	NHzsR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkXjTWM2OD1{LkO3N\|kh\|ryP	NHXyOnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-NEP-1	NWn5UFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4[zd2lEPTB;Mj6zPFc5OyEQvF2=	NYi3N2s5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RS4-11	M2PCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2PYOGlEPTB;Mj61OlAzOyEQvF2=	MljEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HuH-7	NW[3U4VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIjMWG9KSzVyPUKuOVY4ODJizszN	Mnz3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A101D	NFfGVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVHORXhzUUN3ME2yMlYyOzN6IN88US=>	NIOzdpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KG-1	NGjZcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIH0TI1KSzVyPUKuOlc6OjRizszN	Mn:4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KALS-1	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mny0TWM2OD1{Lk[5OlM{KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
VMRC-RCZ	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{\4UGlEPTB;Mj63O\|MzQCEQvF2=	M3XzRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SK-UT-1	M37zRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2D5UWlEPTB;Mz6xOVMyKM7:TR?=	MmTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SW962	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Moj0TWM2OD1\|LkKwN\|UzKM7:TR?=	NVnCd\|ZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
DBTRG-05MG	M2ezUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoflTWM2OD1\|LkK4NFg2KM7:TR?=	NILQRXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
PANC-08-13	M3XLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4H5[WlEPTB;Mz60NVI4QCEQvF2=	NVXEXFVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
QIMR-WIL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlvOTWM2OD1\|LkSxN\|QyKM7:TR?=	M3O0WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SK-MEL-30	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWPJR\|UxRTNwNEK1PVgh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
697	M3;T[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFfISpdKSzVyPUOuOFQ6QTNizszN	MnfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NY	NV:zO5IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmjETWM2OD1\|LkS1NFIzKM7:TR?=	MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ES7	NGDzV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGHL[o5KSzVyPUOuOFY4OjlizszN	MoDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
JVM-3	M2n2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{X1eWlEPTB;Mz60PFA4PyEQvF2=	NYPD[ppkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
U031	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVzHem1{UUN3ME2zMlU6OzZ6IN88US=>	Mki2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
BHT-101	NIq2bGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1G5bmlEPTB;Mz61PVk5PSEQvF2=	NXPQdXBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
8305C	NUH6bmlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlS0TWM2OD1\|Lk[xO\|M3KM7:TR?=	NHywclM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MG-63	M3Xxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NInNem1KSzVyPUOuOlI3PzZizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NOS-1	NELLXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUTJR\|UxRTNwNkWzNVIh\|ryP	NXrG[WN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
YH-13	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV;JR\|UxRTNwOEexPFkh\|ryP	MlnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LXF-289	NV3mbYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVHJR\|UxRTNwOUGwOFEh\|ryP	NVHDOJhoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
GOTO	NU\nZpdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUDJR\|UxRTNwOUG0PUDPxE1?	NEnsUms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
EKVX	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1m4PGlEPTB;ND6yNlUzPCEQvF2=	M3S3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CAL-51	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYHJR\|UxRTRwMkS4OVQh\|ryP	MlXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
AN3-CA	NF3YN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlfXTWM2OD12LkK1PFE{KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
IA-LM	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlzXTWM2OD12LkK3PVM2KM7:TR?=	MmHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KU-19-19	NHztcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFLOWGVKSzVyPUSuN\|I6OjFizszN	M{DUflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
A704	M1GyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTRwNEC4PFgh\|ryP	M4XTW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
RH-18	NF3DOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4jKUmlEPTB;ND60OFk2OyEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
IST-MEL1	M{DiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWDWWm5mUUN3ME20MlU5OjZ\|IN88US=>	M4j1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LU-134-A	M4HXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmnOTWM2OD12LkW5Olg2KM7:TR?=	NGHQZlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SF126	M3m0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWLJR\|UxRTRwNkC3NVUh\|ryP	M2jZR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
EFO-27	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4mxTGlEPTB;ND62OlUzPSEQvF2=	NILwXHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SN12C	M3H2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVrNe3hvUUN3ME20MlcyQDl6IN88US=>	NGm4cVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
L-363	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M13y[WlEPTB;ND63O\|EyPiEQvF2=	NFjy[ZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MEL-HO	M4HTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M120XWlEPTB;ND63O\|k5QSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
TYK-nu	MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUX6fI5YUUN3ME20MlgxOTJ6IN88US=>	NHrlWpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MDA-MB-415	NIHtRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MonHTWM2OD13LkCwN\|E1KM7:TR?=	NWm2PHV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HCC70	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2fJbWlEPTB;NT6wN\|k{QSEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
IGROV-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVjJR\|UxRTVwMkWyPVIh\|ryP	NFTSUlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1355	NF7HS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXXJR\|UxRTVwMkm2JO69VQ>?	M1rVW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
23132-87	M2TUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml[yTWM2OD13LkOyNFI1KM7:TR?=	NGT0eI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NB69	NHL2XXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmfWTWM2OD13LkOyOFIh\|ryP	NYXFVm8{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HSC-2	NUTvOVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVrJR\|UxRTVwNEG3O\|Mh\|ryP	NGXoS4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KYSE-410	M{XRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXrJR\|UxRTVwNEe2N\|Yh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
GCIY	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXzJR\|UxRTVwNUGzO\|gh\|ryP	MoLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A427	NFPiPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXXtR3ZtUUN3ME21MlU{PjZzIN88US=>	M17Y[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
ChaGo-K-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUPjflc2UUN3ME21MlU3PTl7IN88US=>	NHXQSYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
PFSK-1	NED2cm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1TNPGlEPTB;NT62NlE6PCEQvF2=	Ml;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
MLMA	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX7JR\|UxRTVwOEO2NFYh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RVH-421	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX;FeWlkUUN3ME22MlA4OzN6IN88US=>	NYq0WoJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LB1047-RCC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NITjW2xKSzVyPU[uNVc2OjJizszN	NV31fWY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MHH-NB-11	M4Xy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH6wcG1KSzVyPU[uN\|I4OjFizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3zFO2lEPTB;Nj62N\|I6OSEQvF2=	NYHYUVRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
UM-UC-3	M1fa[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFHBfWpKSzVyPU[uOlQ{OzRizszN	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
IST-SL1	M4KzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoHaTWM2OD14Lk[5N\|Y6KM7:TR?=	MoT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NB14	M1\NN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTZwN{m3OlEh\|ryP	Mn3NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NBsusSR	NFy5RpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYrSN4xMUUN3ME22MlgzPTB{IN88US=>	NUH1TmdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
D-263MG	Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mm\mTWM2OD14LkmxNFY5KM7:TR?=	Mn7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H2347	NWDNO3U1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2\CdWlEPTB;Nj65N\|IyOyEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
ES8	NEnZSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWXjRnZFUUN3ME22Mlk4PTh6IN88US=>	NEDJ[G89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
786-0	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEHEdXNKSzVyPUeuNFk4QDZizszN	NFPhWFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
EPLC-272H	M3XXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFHQWJpKSzVyPUeuNVYzPDZizszN	NEPOOFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CAPAN-1	NF7IUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3XrOmlEPTB;Nz6yOFM2QSEQvF2=	NV7HU\|JwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H82	NWm3dGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWjY[WhCUUN3ME23MlI3PjV7IN88US=>	M1P2PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
G-402	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mo\5TWM2OD15LkOwNFUyKM7:TR?=	M4qxXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SW982	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NETaOWhKSzVyPUeuN\|AzODNizszN	NGC5VY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
OVCAR-4	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1y5eWlEPTB;Nz6zNVMzQCEQvF2=	NWHVfnllRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KARPAS-299	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M33RUmlEPTB;Nz6zNlYzOiEQvF2=	M3L6[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MIA-PaCa-2	NH7IbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXTJR\|UxRTdwM{[4NlMh\|ryP	M2[3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
AU565	NI[2OZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{nnSmlEPTB;Nz61PVg{OyEQvF2=	M4jYTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
GAMG	NFPFNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3jKPGlEPTB;Nz62OFE{OSEQvF2=	NIr6[\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HuO9	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUHJR\|UxRTdwN{G3OFMh\|ryP	MlToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ACN	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIK4elZKSzVyPUeuO\|Q{OyEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RO82-W-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Moe4TWM2OD15Lke0OVM{KM7:TR?=	MmjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NKM-1	NIPYXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGG5bHhKSzVyPUeuO\|Q6PTVizszN	Mn;wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CAL-12T	NGfXVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml3FTWM2OD15Lkm0N\|UzKM7:TR?=	NEDHZWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
FADU	Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGfIcGpKSzVyPUiuNFM3PTRizszN	M3;EPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H28	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF;OSnlKSzVyPUiuNVY6PjJizszN	M1XCU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LCLC-97TM1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXfjXXR4UUN3ME24MlIyOTJ{IN88US=>	M3vqbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CHP-134	NHfEZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHPMfldKSzVyPUiuNlQyQDVizszN	M4\tS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HT-1080	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFvyXY5KSzVyPUiuNlUxQTNizszN	M4LBT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
PC-3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV\JR\|UxRThwMkezPVIh\|ryP	NHfsSFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SNU-449	M4Dqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHWyVo9KSzVyPUiuNlc6OyEQvF2=	Ml3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
VA-ES-BJ	NIDEd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX7jd5lTUUN3ME24MlM1Pjh4IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HT	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlfjTWM2OD16LkO2OFkh\|ryP	M1jTPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HOS	M2ryd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnjCTWM2OD16LkO3OVg6KM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KNS-62	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXW1SVdJUUN3ME24MlM4PzZ{IN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
OAW-42	NFL6V5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV7JR\|UxRThwOUW5OlQh\|ryP	MmDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A549	NXjDTVRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX\ob3YyUUN3ME25MlA6PjF{IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CAKI-1	NFfHZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUnJR\|UxRTlwMU[2NUDPxE1?	M{fWfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HCC1937	NIjLW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUPLdWhKUUN3ME25MlY6QDZ3IN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
GI-ME-N	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{OzVWlEPTB;OT63NFE{PyEQvF2=	M1XmcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
DU-4475	NXP6fnNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{L4ZWlEPTB;OT65Olk{QSEQvF2=	NUfsTXlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
EM-2	MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF[2cJNKSzVyPUGwMlI1OjZizszN	NFi3[lE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1755	M3;HN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGr4RoFKSzVyPUGwMlI1OjhizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H1437	M4mxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWDJTFhXUUN3ME2xNE42PzJ3IN88US=>	NFXq[IQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
VM-CUB-1	NIXtT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlG2TWM2OD1zMD62NVY1KM7:TR?=	MnzOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A2058	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoLFTWM2OD1zMD62OFA1KM7:TR?=	NGjjRnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BPH-1	NXf5NmczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1zRSGlEPTB;MUCuO\|E1PSEQvF2=	MmrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NB5	MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NE[3NZVKSzVyPUGwMlc2PTlizszN	M2C3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
G-401	NGfpdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NULMVYY1UUN3ME2xNE44PjJ4IN88US=>	MmjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CAL-72	NUXC[FJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlnlTWM2OD1zMD64NFk1KM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-MEL-28	NXLZbGY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{noOmlEPTB;MUCuPFIxOiEQvF2=	NVPGXo9MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
C32	NFHrfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NU\WSVBOUUN3ME2xNE45OzR5IN88US=>	MknZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1155	NI\FSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MknETWM2OD1zMD64N\|c3KM7:TR?=	NXHhfHY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BB49-HNC	NYTRbG1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2O0SGlEPTB;MUCuPFU5PiEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
GMS-10	MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkK1TWM2OD1zMD64PVcyKM7:TR?=	NFn0TJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
K5	NH;OfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmrITWM2OD1zMD65NFcyKM7:TR?=	M1nNdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
OS-RC-2	NH3YTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYqzR2FYUUN3ME2xNU4xPTV7IN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HTC-C3	MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVHJR\|UxRTFzLkC3NVQh\|ryP	NHfWbWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
LB996-RCC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFvQcGpKSzVyPUGxMlA4OjNizszN	NEi4Z4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1563	MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1HBNmlEPTB;MUGuNVAyOSEQvF2=	M3HxbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CAL-54	M2rwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV;JR\|UxRTFzLkS4NVEh\|ryP	M1LoclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
WM-115	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn\pTWM2OD1zMT62PFI1KM7:TR?=	M3HQTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
COLO-684	NYXuXpNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlPFTWM2OD1zMT63NlY4KM7:TR?=	MnPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HOP-62	NYf0eIQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1rscGlEPTB;MUGuO\|UxQCEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H650	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYTN[nliUUN3ME2xNU45QTZzIN88US=>	NICwTIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TE-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnHsTWM2OD1zMT65N\|E2KM7:TR?=	NVrDVGIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
COLO-679	NHLlfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mn3tTWM2OD1zMT65OFYh\|ryP	NGDSSYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
FTC-133	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1fqNmlEPTB;MUKuNFA4PiEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-283MED	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVfpeXpOUUN3ME2xNk4xPTZ7IN88US=>	MknRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SK-PN-DW	M1rOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M13sOmlEPTB;MUKuNVkxOiEQvF2=	NGjEOJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BALL-1	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXjJR\|UxRTF{LkK2OlIh\|ryP	NU\kTpFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
GT3TKB	MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFHVdHdKSzVyPUGyMlMxPzRizszN	M1HPc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HOP-92	M4fMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml7WTWM2OD1zMj61NlM{KM7:TR?=	NVS0U4V2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
M14	MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NY\KOZlwUUN3ME2xN{4xOzN3IN88US=>	M3PJdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SKG-IIIa	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVrDW2s{UUN3ME2xN{4xPTV2IN88US=>	MnrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
Becker	NIPJcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVzJR\|UxRTF\|LkC1PEDPxE1?	NF70XlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ES5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVq4T49LUUN3ME2xN{4yOzV4IN88US=>	NGD2TYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H2030	NGfF[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFXjbHlKSzVyPUGzMlIxPjJizszN	NFvCVoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SNU-423	NFLxTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1jUV2lEPTB;MUOuN\|gyKM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CP50-MEL-B	M17RNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEXyepNKSzVyPUGzMlYzOzJizszN	M2nmT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H1092	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWDJR\|UxRTF\|Lke0O\|Uh\|ryP	NGXOcos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
8-MG-BA	NVXh[2ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYXOclRTUUN3ME2xN{44PTF\|IN88US=>	M4L1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CAL-27	NV;6fWY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVj2VWR4UUN3ME2xOE4xPzJ5IN88US=>	NFPIRlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
AGS	M1;zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIXpfHVKSzVyPUG0MlE{OTlizszN	NEPxbY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MZ2-MEL	NFjZXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4Gw[mlEPTB;MUSuNVQ5QCEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BFTC-909	M1\L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIXWOIlKSzVyPUG0MlUxPTVizszN	NFftR\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
D-566MG	NYLpVmZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnX5TWM2OD1zND63O\|A3KM7:TR?=	NIPDelc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MZ7-mel	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV7JR\|UxRTF3LkGwOlch\|ryP	NV3JTFBVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TE-5	MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3vqfmlEPTB;MUWuNlM{OyEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
647-V	NYD3dIJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVXJR\|UxRTF3LkK3NFUh\|ryP	NVy3N\|VuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
DMS-114	NUPCeFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFnGd4xKSzVyPUG1MlMzQTFizszN	NFHvR\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ME-180	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVvUNlNVUUN3ME2xOU41Pzh\|IN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MS-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVjKRYZ3UUN3ME2xOU42PjJ\|IN88US=>	NHnPW\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NUGC-3	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX;JR\|UxRTF3Lk[yOFUh\|ryP	NUj3bZZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
GB-1	MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnfuTWM2OD1zNT62OFM4KM7:TR?=	Mnq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LOXIMVI	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mo\YTWM2OD1zNT64PVE6KM7:TR?=	MlHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1304	M3\pRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3S2dGlEPTB;MUWuPFkzQCEQvF2=	NV3NelB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KURAMOCHI	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mn7HTWM2OD1zNT65O\|Eh\|ryP	M3y0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SW1783	NVfzXpdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWLJR\|UxRTF4LkC5PVMh\|ryP	NXryO5NVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
EGI-1	MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV7GVpNZUUN3ME2xOk42OzZ3IN88US=>	NFP6WoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KGN	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWTJR\|UxRTF4LkW1PFYh\|ryP	M{DYWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
PANC-03-27	NXOwWYhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmeyTWM2OD1zNj63OlYzKM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RH-1	NWnMVFlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkPmTWM2OD1zNj64NlUh\|ryP	MlfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HT-1376	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIDHcmNKSzVyPUG2Mlg1PDZizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
ZR-75-30	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXnJR\|UxRTF4LkmzOlEh\|ryP	M33TelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TI-73	M2jOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUjBdncyUUN3ME2xOk46PDB6IN88US=>	NUTaU4dnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TK10	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1jRdGlEPTB;MUeuNFA4QSEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SW684	NV;UR49CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUPwNpY4UUN3ME2xO{4xOTV2IN88US=>	NX[xcYZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RPMI-8866	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHzlUlJKSzVyPUG3MlA3QTlizszN	MnnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LNCaP-Clone-FGC	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWjJR\|UxRTF5LkWyNFEh\|ryP	NVPmdIRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H2291	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{DIVmlEPTB;MUiuOFM1PSEQvF2=	M1vh[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
T47D	NH30c3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4\nN2lEPTB;MUiuOFg5KM7:TR?=	NFOwboU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A204	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MW\JR\|UxRTF6LkW0OVIh\|ryP	NF;JT4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HT-144	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmCyTWM2OD1zOD63OFI4KM7:TR?=	NYnhe3dqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MDA-MB-361	MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NG\KZllKSzVyPUG5MlA4OTRizszN	Mo\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HCC1806	NXnLUmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmLNTWM2OD1zOT6xOVkyKM7:TR?=	M4fZZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H596	NFrtbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmL5TWM2OD1zOT62N\|kyKM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
K-562	NWDU[XpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVnJR\|UxRTF7Lki5NlYh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-336MG	M2TtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUDSVXh{UUN3ME2xPU46OzJ{IN88US=>	M3;YUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SK-MEL-2	M1jPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXzJR\|UxRTJyLkG1OVkh\|ryP	M{TWVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HEC-1	MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NE[w[FVKSzVyPUKwMlQ6PzhizszN	MnjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
EW-13	M3j6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVLJR\|UxRTJyLkW0OFMh\|ryP	NHXJZVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
Hs-578-T	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXXJR\|UxRTJyLkW1PFMh\|ryP	Ml[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SJSA-1	MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3iwOmlEPTB;MkCuOVY5QCEQvF2=	MmPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
RCC10RGB	NF\ybWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NU\r[Fc2UUN3ME2yNE43PzF7IN88US=>	NEXXcHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
LAN-6	NFPa[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mnf1TWM2OD1{MT6wN\|k3KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H1048	NG\wdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHjCSllKSzVyPUKxMlIzPThizszN	NXHGcFBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CW-2	NGjMVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnPQTWM2OD1{MT6yO\|A2KM7:TR?=	NUHTSnQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HCC2157	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWHM[\|JRUUN3ME2yNU4{PiEQvF2=	NX\rcJZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
EW-22	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmTSTWM2OD1{MT6zO\|Yh\|ryP	M1njSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
A253	NHfKNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEf5cJpKSzVyPUKxMlQ1QDFizszN	M4TONFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
BE-13	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2rZTmlEPTB;MkGuOlEyOyEQvF2=	MnnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KINGS-1	M4OxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXfJR\|UxRTJzLk[zNVYh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
ETK-1	Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXXJR\|UxRTJzLkixOVIh\|ryP	M1zGTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H2452	NELXS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NH7DS5RKSzVyPUKxMlg3PDdizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HPAF-II	NFjSWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIXNXnZKSzVyPUKxMlg6OjNizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-542MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIXqS5lKSzVyPUKxMlkxPjlizszN	NIXmTnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H630	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVfJR\|UxRTJ{LkCyPVYh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
TGBC11TKB	MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2nGNGlEPTB;MkKuNFQ6KM7:TR?=	NHjKSXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BCPAP	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXzJR\|UxRTJ{Lk[xNUDPxE1?	M{DPb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HLE	NGLsfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHvvUZFKSzVyPUKyMlY6PyEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H727	NWTFNGdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnHFTWM2OD1{Mj63N\|Uh\|ryP	MlW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
RD	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mny0TWM2OD1{Mj63OVE5KM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H522	NYDxT3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MofyTWM2OD1{Mj64OFMyKM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CGTH-W-1	MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWnJR\|UxRTJ\|LkC2OFEh\|ryP	NVH6e4VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SK-LU-1	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYD4Z5Q1UUN3ME2yN{41Pjh\|IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BB65-RCC	NFPvb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYfJR\|UxRTJ\|Lke4OlMh\|ryP	MlrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HSC-3	NXjOPWc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVTJR\|UxRTJ\|Lki1Nlch\|ryP	MkL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SK-MES-1	NXfUZpZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVuxOIg1UUN3ME2yOE4xOTZzIN88US=>	M{TiN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
DB	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXTJR\|UxRTJ2LkGwNlgh\|ryP	NH3FXVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HO-1-N-1	NYracXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYDJR\|UxRTJ2LkOwPVMh\|ryP	M{XhSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MKN1	M3rre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml7VTWM2OD1{ND62PEDPxE1?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MN-60	NV;WTpdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFnVeJhKSzVyPUK0Mlg2OTlizszN	NFyxRlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
8505C	M2jCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFPSSnpKSzVyPUK1MlE5PDVizszN	MmrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
COLO-320-HSR	M4\p[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4TJPWlEPTB;MkWuNlIxQCEQvF2=	M3LlTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
BB30-HNC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWHOfG5vUUN3ME2yOU4zPDh\|IN88US=>	MlTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KM12	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXnJR\|UxRTJ3LkW4NFch\|ryP	M3vOTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NB13	M2nOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmrKTWM2OD1{NT61PFk5KM7:TR?=	NFPofIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HCC2998	NHrXeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlzmTWM2OD1{Nj6wNlg{KM7:TR?=	MmDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
U-118-MG	M{\BW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVe2ZVk2UUN3ME2yOk4xQDB6IN88US=>	NYHvWoZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NB10	NI\yPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVK5c4g2UUN3ME2yOk4zOzRizszN	NGPXTow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-LMS-1	M2jNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFvVNpJKSzVyPUK3MlA4ODRizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SW1573	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mm\TTWM2OD1{Nz6xNUDPxE1?	MkHmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LB373-MEL-D	NYq0c\|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2HpR2lEPTB;MkeuNVI6PCEQvF2=	Mo\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
DK-MG	MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NETXT2hKSzVyPUK3MlE5OTdizszN	NFfieok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RMG-I	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGmzfGVKSzVyPUK3MlIxOjlizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SW1088	Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWPXXWcxUUN3ME2yO{42ODR{IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-OV-3	MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MY\JR\|UxRTJ5Lke1PVMh\|ryP	NXnLRXN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KP-N-YN	NUDMO2w4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVLJR\|UxRTJ5LkiwOFMh\|ryP	NVjkbVdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RPMI-7951	Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEC1UWVKSzVyPUK4MlI1PTZizszN	MkX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CaR-1	MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml;XTWM2OD1{OD61OVgzKM7:TR?=	Mk\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
MKN7	NXTCSm15T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGTXWnlKSzVyPUK4MlU6PjRizszN	NX7GUXUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CHP-212	MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1j5[WlEPTB;MkiuO\|QxOSEQvF2=	MmXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KYSE-450	NGTwbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYnERm9HUUN3ME2yPE45ODlzIN88US=>	NXvXZVdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RXF393	MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVfJR\|UxRTJ7LkK5NFYh\|ryP	NE\mOXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
P30-OHK	M2[wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M13JNmlEPTB;MkmuN\|A1QCEQvF2=	NHnPbFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
Ca9-22	MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVz2cW05UUN3ME2yPU41Ojl7IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RT-112	NU[wRoM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2fXeGlEPTB;MkmuOFYyOSEQvF2=	NVPXWZdsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
ES1	NVvoUGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn7oTWM2OD1{OT64OVQ1KM7:TR?=	Mn\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HCE-4	NEDIXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWX4Tpk{UUN3ME2yPU45Pzh4IN88US=>	NX7MT2toRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
AM-38	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmCyTWM2OD1\|MD6wOlA3KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
AsPC-1	NXvPSmQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWT1PJdYUUN3ME2zNE45ODV\|IN88US=>	NX;tdVhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TE-9	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MljxTWM2OD1\|MD64O\|M4KM7:TR?=	NH3QNmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HuP-T4	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2K1W2lEPTB;M{CuPVY{QCEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LB2518-MEL	MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFfsSY9KSzVyPUOxMlA4PDRizszN	NIi3TWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1703	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlLRTWM2OD1\|MT6wPVA2KM7:TR?=	M2e4U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H2228	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGLXPXlKSzVyPUOxMlQ3PTFizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SCC-4	MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIi1TFdKSzVyPUOxMlkyQDFizszN	M1X4WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
KNS-81-FD	MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHfEdZBKSzVyPUOyMlAyOjhizszN	M4jWe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	NVHETXFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYXWcY9tUUN3ME2zNk4xPzN7IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
Daoy	M4rJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGfURYJKSzVyPUOyMlA5OzhizszN	MlTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ES4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVnXUINOUUN3ME2zNk4{QTJ{IN88US=>	NUfnZVVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MHH-ES-1	M1LXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVvJR\|UxRTN{LkS4O\|Ih\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
C-33-A	M3vDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVjyS215UUN3ME2zNk44PzJ6IN88US=>	MoOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
BHY	M4fQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2DoZmlEPTB;M{KuPVQ6PSEQvF2=	NGWxTpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
Detroit562	M4rxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXvJR\|UxRTN\|Lk[2OVch\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
EW-1	M{G1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWDmc2g6UUN3ME2zN{46OzJ{IN88US=>	MnLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1395	M2LNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M17LbWlEPTB;M{SuNFc6QSEQvF2=	M1;Yc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
KM-H2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXvQWoFSUUN3ME2zOk41PzR\|IN88US=>	NYnMcIF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H520	NH2zZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{HTUWlEPTB;M{[uO\|U1OSEQvF2=	NEXGe\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
D-392MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV7JR\|UxRTN5LkOzOFQh\|ryP	MkjJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NOMO-1	NXXvXZo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFTCPG1KSzVyPUO3MlgxQDlizszN	NEjtdVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TE-6	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXHtPWF4UUN3ME2zPE4yOjRizszN	NXnVfFJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HT-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1fye2lEPTB;M{iuOFQ{PiEQvF2=	M4nFc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
RPMI-8226	NYrENIxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUXtc3B[UUN3ME2zPE46PTF7IN88US=>	MorFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
U251	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnfnTWM2OD1\|OT6wNVI1KM7:TR?=	NEO5[IE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GCT	NFrXdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml3pTWM2OD1\|OT6xPFUzKM7:TR?=	Mnm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A431	MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV;F[IJWUUN3ME2zPU4yQDl2IN88US=>	M1vCUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TE-12	M2fPbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWL4cFY1UUN3ME2zPU4zPDR6IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HMV-II	NUHiS\|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M33KWmlEPTB;M{muOVA1PyEQvF2=	Mnq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
IST-MES1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWPWVpRSUUN3ME20NE4yPTB{IN88US=>	Mk\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SW13	NIrHfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3[zb2lEPTB;NECuOVE6KM7:TR?=	NIXXVpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SF295	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF;WU3pKSzVyPUSwMlgxPjZizszN	M1ntR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MDA-MB-157	MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoXPTWM2OD12MD65OFYzKM7:TR?=	M4Xje\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TE-1	NHnVdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX;JR\|UxRTRzLki3NVQh\|ryP	M2HRW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HuCCT1	NHjrfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWHHfoJMUUN3ME20Nk42Ojh7IN88US=>	NWfYWJhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KYSE-510	NETJNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFnNdohKSzVyPUSzMlE4PTRizszN	M1vPPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H358	NVWxZZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2PReGlEPTB;NESuNFMxPCEQvF2=	NEfzXWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SW900	M1K5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlXlTWM2OD12ND6wO\|U5KM7:TR?=	NGHRdHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CAS-1	NUHvfY1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHy0c2NKSzVyPUS0MlA6QTFizszN	NEjQfnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TE-8	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NE\1W5ZKSzVyPUS0MlU3PThizszN	Mk\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV7ZTpo3UUN3ME20OE43OTF{IN88US=>	M1e4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
YKG-1	NY\mWnl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEX1eXdKSzVyPUS0Mlc5OSEQvF2=	M4q2OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SNU-C2B	NWL6[Yg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXnJR\|UxRTR2Lke5NFMh\|ryP	NV\hZ5ZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LCLC-103H	NUn0WFg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MX;JR\|UxRTR2Lki3NFMh\|ryP	MmnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
U-87-MG	Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M33hVWlEPTB;NEWuNVAzOiEQvF2=	NYPCZVV1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HAL-01	Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3G4SWlEPTB;NEWuNVM4QSEQvF2=	NXn2NZB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
OVCAR-8	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NETmTJhKSzVyPUS1MlM2PjRizszN	Mny4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KYSE-150	MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlvlTWM2OD12Nz6xNFUzKM7:TR?=	MmTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
OE33	M{DmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGDPOXFKSzVyPUS3MlE1OjlizszN	M{fxXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CAL-62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVyxbVY1UUN3ME20O{41ODZ6IN88US=>	NV7Db4x[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TCCSUP	NFjFNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEDB[25KSzVyPUS3MlYzPjRizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
H4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXjJR\|UxRTR5Lk[2NlEh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CP66-MEL	NFXy[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2Lk[2lEPTB;NEiuNFcxPCEQvF2=	Moe3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SNB75	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml23TWM2OD12OD6xPFc1KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
Mo-T	M4fz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGfhTZpKSzVyPUS4MlI4QSEQvF2=	M{TqclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
BT-549	M37o[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{\kNWlEPTB;NEiuN\|czQSEQvF2=	NHzRcFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
IGR-1	MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFXzWZlKSzVyPUS4MlY3PDVizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H1299	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWTJR\|UxRTR6LkeyOFgh\|ryP	M2XlfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
ALL-PO	NHHqRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml\ZTWM2OD12OT65NlY5KM7:TR?=	MlixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CLL	NHH4OodHfW6ldHnvckBie3OjeR?=			Mlf2TY5pcWKrdHnvckBw\iCGTlGtVGsh[XW2b4Doc5NxcG:{eXzheIlwdiCjdDDT[ZIzODV4IILld4llfWViaX6gbJVu[W5iQ1zMJINmdGy\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4QtKEmFNUCgQUAxNjB\|IN88UU4>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh\|NUi3NEc,OjJ6M{W4O\|A9N2F-
HeLa	MVfGeY5kfGmxbjDhd5NigQ>?			MUnJcohq[mm2aX;uJI9nKESQQT3QT{BifXSxcHjvd5Bpd3K7bHH0bY9vKGG2IGOyNFU3KGmwIHj1cYFvKEinTHGgZ4VtdHNuIFXDOVAhRSByLkKxNkDPxE1w	MonWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUW4N\|YoRjJ\|OEW1PFM3RC:jPh?=
CHO	NULiZ\|A6TnWwY4Tpc44h[XO\|YYm=			M2XzNGlvcGmkaYTpc44hd2ZiaIXtZY4hTVKJIHX4dJJme3OnZDDpckBkcXOjcILp[IUhfHKnYYTl[EBEUE9iY3XscJMh[nliSX;uJHdwemu\|IHHzd4F6NCCLQ{WwJF0hOTRizszNMi=>	NGLocJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1OVg{Pid-MkO4OVU5OzZ:L3G+
A673	NYK3UWMxeUiWUzDhd5NigQ>?			NXrFd3VYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	M4q1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	NUfnNXl2eUiWUzDhd5NigQ>?			Mn\idWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	MmTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NIPw[XNyUFSVIHHzd4F6			MkK2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	Mn;JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	NX[xd2R7eUiWUzDhd5NigQ>?			MkDTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	NHy4WFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NHjLT2dyUFSVIHHzd4F6			NF7Oc2FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	NWfzbG9lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	M1GwSZFJXFNiYYPzZZk>			MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	M1fQTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MmT3dWhVWyCjc4PhfS=>			MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	M37SU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	M4HYdJFJXFNiYYPzZZk>			NWPDOIs4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	M{XMc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	NVLrXmhueUiWUzDhd5NigQ>?			NEHLTnVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NU\ROoo5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	MYfxTHRUKGG\|c3H5			M1;xcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NImyfWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MlrXdWhVWyCjc4PhfS=>			NFvrZWRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NIfCfmxyUFSVIHHzd4F6			MmrtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NHz0c249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	NXXoXGxieUiWUzDhd5NigQ>?			MlTMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MXTxTHRUKGG\|c3H5			MkjOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	NHXP[XM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
INA-6	NIfwOGxHfW6ldHnvckBie3OjeR?=	MkTPNVAhfU1?	NULPemxHPCCqcoO=	NV;RSlhQUW6qaXLpeIlwdiCxZjDo[YF1KHOqb3PrJJJme3CxboPlJIlvKGi3bXHuJGlPSS14IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBJW0ZvMTDt[YRq[XSnZDD1dJJm\3WuYYTpc44hd2ZidHjlJGhUWDd{IIDyc5RmcW5iZYjwdoV{e2mxbjDheEAyOCC3TTDwdoVqdmO3YnH0[YQh\m:{IESgbJJ{KG[xbHzve4VlKGK7IFjTVFkxKGmwaHnibZRweiCjbnSgTHNTKGmwZIXj[ZIhVl[SLVHVXVkzOiCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1KGi{	M3LH[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEWzPVMyLz5{OES1N\|k{OTxxYU6=
INA-6	NIXmVFJHfW6ldHnvckBie3OjeR?=	Mk\hNVAhfU1?	NVzZO45[PCCqcoO=	NUDrPFZ3UW6qaXLpeIlwdiCxZjDo[YF1KHOqb3PrJJJme3CxboPlJIlvKGi3bXHuJGlPSS14IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBJW0ZvMTDt[YRq[XSnZDD1dJJm\3WuYYTpc44hd2ZidHjlJGhUWDd{IH3SUmEh\XiycnXzd4lwdiCjdDCxNEB2VSCycnXpcoN2[mG2ZXSg[o9zKDRiaILzJIZwdGyxd3XkJIJ6KEiVUEmwJIlvcGmkaYTvdkBidmRiSGPSJIlv\HWlZYKgUnZRNUGXWUmyNkBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjC0JIhzeyCk	NHLubmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES1N\|k{OSd-Mki0OVM6OzF:L3G+
INA-6	M2XMZWZ2dmO2aX;uJIF{e2G7	MknlNVAhfU1?	MVe0JIhzew>?	MV3Ec5dvemWpdXzheIlwdiCxZjDOWnAuSVW\OUKyMYlv\HWlZXSgTHNHNTFicILveIVqdiCneIDy[ZN{cW:wIHnuJIh2dWGwIFnORU03KGOnbHzzJIF1KDFyIIXNJJBz\WmwY4XiZZRm\CCob4KgOEBpenNiZn;scI94\WRiYomgUnZRNUGXWUmyNkBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k	NVjrZZRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OVM6OzFpPkK4OFU{QTNzPD;hQi=>
INA-6	MofNSpVv[3Srb36gZZN{[Xl?	NF[1eoIyOCC3TR?=	MXW0JIhzew>?	MVHJcohq[mm2aX;uJI9nKE6YUD3BWXk6OjJvaX7keYNm\CCKU1[tNUBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTW5CNTZiY3XscJMh[XRiMUCgeW0heHKnaX7jeYJifGWmIH\vdkA1KGi{czDmc4xtd3enZDDifUBPXlBvQWXZPVIzKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	NH63Wok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES1N\|k{OSd-Mki0OVM6OzF:L3G+
INA-6	MkjISpVv[3Srb36gZZN{[Xl?	Mlz5NVAhfU1?	NH3ic3M1KGi{cx?=	Mlv1SI94dnKnZ4XsZZRqd25ib3[gUnZRNUGXWUmyNk1qdmS3Y3XkJGhUTi1zIH3SUmEh\XiycnXzd4lwdiCrbjDoeY1idiCLTlGtOkBk\WyuczDheEAyOCC3TTDwdoVqdmO3YnH0[YQh\m:{IESgbJJ{KG[xbHzve4VlKGK7IF7WVE1CXVl7MkKgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiNDDodpMh[nliUmStVGNTKG2ndHjv[C=>	NXu5PW9PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OVM6OzFpPkK4OFU{QTNzPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51; PubMed: 29344644 Oncol Rep SUNE1 cells were irradiated with 5 Gy in the presence or absence of NU7441 (2 µM). The expression of cell cycle checkpoint proteins and double strand break repair proteins was assayed by western blot analysis at 6 or 12 h post-IR. p-mTOR(Ser2448) / mTOR / p-S6K(Thr389); PubMed: 25714019 Oncotarget Phosphorylation of mTOR and p70S6K were detected by Western blot analysis 24 hours after treatment.	29344644 25714019

In vivo

NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research:

^[2]

- Collapse

Cell lines: SW620, LoVo, V3-YAC and V3 cells
Concentrations: 0.5 μM or 1 μM
Incubation Time: 17 hours
Method:
The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

(Only for Reference)

Animal Research:

^[2]

- Collapse

Animal Models: Female rude mice bearing SW620 xenografts
Dosages: 10 mg/kg
Administration: Intraperitoneally administrated
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	0.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please suggest formulations of the drug for in vivo injection?
Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.
Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 : DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.
Most Potent DNA-PK Inhibitor

PIK-75 : DNA-PK, IC50=2 nM.
Newest DNA-PK Inhibitor

KU-0060648 : Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Classic DNA-PK Inhibitor

NU7026 : Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy. For animal testing, the water-soluble S7306 Dorsomorphin (Compound C) 2HCl is recommended.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
NU7026

NU7026 (LY293646) is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR. NU7026 enhances G2/M cell arrest and apoptosis.
KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)